{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:47:10Z","timestamp":1789757230911,"version":"4.0.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100018421","name":"Institute for Clinical and Translational Science, University of California, Irvine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018421","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The present study tests the hypothesis that mitochondrial genes have retrograde signaling capacity that influences the expression of nuclear genes related to angiogenesis pathways. Cytoplasmic hybrid (cybrid) in vitro cell lines with patient specific mitochondria inserted into an immortalized retinal pigment epithelial cell line (ARPE-19) were used to test this hypothesis. This type of analysis can provide important information to identify the optimal regimen of anti-VEGF treatment, personalizing age-related macular degeneration (AMD) therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Mitochondria deficient ARPE-19 cells (Rho0) were fused with AMD donor\u2019s platelets to create individual cybrid cell lines containing mitochondria from patients with phenotypic AMD disease and nuclear DNA from the immortalized RPE cell line. The cybrids were treated with Ranibizumab (Lucentis, Genentech, San Francisco, CA), at 4 different concentrations for 24\u00a0h, and subsequently the levels of reactive oxygen species (ROS), gene expression for\n                      <jats:italic>VEGF-A<\/jats:italic>\n                      , hypoxia-inducible factor 1-alpha (\n                      <jats:italic>HIF1-a<\/jats:italic>\n                      ) and manganese superoxide dismutase (\n                      <jats:italic>SOD2)<\/jats:italic>\n                      were measured. The clinical evolution of the two AMD-donors were correlated with the molecular findings found in their \u2018personalized\u2019 cybrids.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Cybrids from Patient-01 showed down-regulation of gene expression of\n                      <jats:italic>VEGF-A<\/jats:italic>\n                      and\n                      <jats:italic>HIF-1a<\/jats:italic>\n                      at both 1X and 4X Ranibizumab concentrations. Patient-01 AMD cybrid cultures had an increase in the ROS levels at 1X (P\u2009=\u20090.0317), no changes at 2X (P\u2009=\u20090.8350) and a decrease at 4X (P\u2009=\u20090.0015) and 10X (P\u2009=\u20090.0011) of Ranibizumab. Clinically, Patient-01 responded to anti-VEGF therapy but eventually developed geographic atrophy. Patient-02 cybrids demonstrated up-regulation of gene expression of\n                      <jats:italic>VEGF-A<\/jats:italic>\n                      and\n                      <jats:italic>HIF-1a<\/jats:italic>\n                      at Ranibizumab 1X and 4X concentrations. There was decreased ROS levels with Ranibizumab 1X (P\u2009=\u20090.1606), 2X (P\u2009=\u20090.0388), 4X (P\u2009=\u20090.0010) and 10X (P\u2009=\u2009\u2009&lt;\u20090.0001). Clinically, Patient-02 presented with a neovascular lesion associated with a prominent production of intraretinal fluid in clinical follow-up requiring regular and repeated intravitreal injections of Ranibizumab with recurrent subretinal fluid.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our cybrid model has the potential to help personalize the treatment regimen with anti-VEGF drugs in patients with neovascular AMD. Further investigation is needed to better understand the role that the mitochondria play in the cellular response to anti-VEGF drugs. Future studies that focus on this model have the potential to help personalize anti-VEGF treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40942-023-00476-7","type":"journal-article","created":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T04:02:18Z","timestamp":1690257738000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The role of mitochondrial genes on nuclear gene expression in neovascular age related macular degeneration: analysis of nuclear VEGF gene expression after ranibizumab treatment in cytoplasmic hybrid retinal pigment epithelial cell lines correlated with clinical evolution"],"prefix":"10.1186","volume":"9","author":[{"given":"Rodrigo Donato","family":"Costa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4816-5838","authenticated-orcid":false,"given":"Farid Jos\u00e9","family":"Thomaz Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Tarek","family":"Moustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shari R.","family":"Atilano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyn","family":"Chwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"C\u00e1ceres-del-Carpi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Hamid","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Cristina","family":"Kenney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baruch D.","family":"Kuppermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,25]]},"reference":[{"key":"476_CR1","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1001\/archopht.122.4.564","volume":"122","author":"DS Friedman","year":"2004","unstructured":"Friedman DS, O\u2019Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122:564\u201372.","journal-title":"Arch Ophthalmol"},{"key":"476_CR2","unstructured":"Emerson GG, Francis PJ, Wilson D, Garner A. Vascular diseases, Chapter 67. In: Klintworth G, Garner A, Editors. Pathophysiology of ocular diseases, 3rd edn. CRC Press; 2008."},{"key":"476_CR3","doi-asserted-by":"crossref","unstructured":"Kenney MC, Hertzog D, Chak G, Atilano SR, Khatibi N, Soe K, Nobe A, Yang E, Chwa M, Zhu F, Memarzadeh M, King J, Small K, Nesburn AB, Boyer DS, Udar N.  Mitochondrial DNA haplogroups confer differences in risk for age-related macular degeneration: a case control study.  BMC Medical Genetics. 2013;9;14(1):4.","DOI":"10.1186\/1471-2350-14-4"},{"key":"476_CR4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/00006982-200502000-00001","volume":"25","author":"AP Adamis","year":"2005","unstructured":"Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina. 2005;25:111\u20138.","journal-title":"Retina"},{"key":"476_CR5","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1001\/archopht.120.3.338","volume":"120","author":"MG Krzystolik","year":"2002","unstructured":"Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol. 2002;120:338\u201346.","journal-title":"Arch Ophthalmol"},{"key":"476_CR6","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1136\/bjophthalmol-2012-301677","volume":"96","author":"HL Deissler","year":"2012","unstructured":"Deissler HL, Deisller H, Lang GE. Actions of bevacizumab and Ranibizumab on Microvascular retinal endothelial cells: similarities and differences. Br J Ophthalmol. 2012;96:1023\u20138.","journal-title":"Br J Ophthalmol"},{"key":"476_CR7","doi-asserted-by":"publisher","first-page":"6781","DOI":"10.1523\/JNEUROSCI.20-18-06781.2000","volume":"20","author":"PA Yourey","year":"2000","unstructured":"Yourey PA, Gohari S, Su JL, et al. Vascular endothelial cell growth factors promote the in vitro development of rat photoreceptor cells. J Neurosci. 2000;20:6781\u20138.","journal-title":"J Neurosci"},{"key":"476_CR8","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.1172\/JCI65157","volume":"122","author":"T Kurihara","year":"2012","unstructured":"Kurihara T, Westenskow PD, Bravo S, et al. Targeted deletion of VegfA in adult mice induces vision loss. J Clin Invest. 2012;122:4213\u2013421.","journal-title":"J Clin Invest"},{"issue":"4","key":"476_CR9","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1136\/bjophthalmol-2018-312691","volume":"103","author":"A Low","year":"2019","unstructured":"Low A, Faridi A, Bhavsar KV, Cockerham GC, Freeman M, Fu R, Paynter R, Kondo K, Kansagara D. Comparative effectiveness and harms of intravitreal antivascular endothelial growth factor agents for three retinal conditions: a systematic review and meta-analysis. Br J Ophthalmol. 2019;103(4):442\u201351. https:\/\/doi.org\/10.1136\/bjophthalmol-2018-312691.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"476_CR10","first-page":"361","volume":"19","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am. 2006;19(3):361\u201372.","journal-title":"Ophthalmol Clin North Am"},{"key":"476_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/aos.13031","author":"K Hatz","year":"2016","unstructured":"Hatz K, Pr\u00fcnte C. Treat and extend versus Pro Re Nata regimens of ranibizumab in neovascular age-related macular degeneration: a comparative 12 Month study. Acta Ophthalmol. 2016. https:\/\/doi.org\/10.1111\/aos.13031.","journal-title":"Acta Ophthalmol"},{"issue":"10","key":"476_CR12","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1136\/bjophthalmol-2015-307299","volume":"10","author":"K Hatz","year":"2016","unstructured":"Hatz K, Pr\u00fcnte C. Changing from a pro re nata treatment regimen to a treat and extend regimen with ranibizumab in neovascular age-related macular degeneration. Br J Ophthalmol. 2016;10(10):1341\u20135. https:\/\/doi.org\/10.1136\/bjophthalmol-2015-307299.","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"476_CR13","doi-asserted-by":"publisher","first-page":"e0137866","DOI":"10.1371\/journal.pone.0137866.eCollection","volume":"10","author":"CM Schmucker","year":"2015","unstructured":"Schmucker CM, R\u00fccker G, et al. Treatment as required versus monthly treatment in the management of neovascular age-related macular degeneration: a systematic review and meta-analysis. PLoS ONE. 2015;10(9):e0137866. https:\/\/doi.org\/10.1371\/journal.pone.0137866.eCollection.","journal-title":"PLoS ONE"},{"issue":"2","key":"476_CR14","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ajo.2007.10.004","volume":"145","author":"CD Regillo","year":"2008","unstructured":"Regillo CD, Brown DM, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008;145(2):239\u201348. https:\/\/doi.org\/10.1016\/j.ajo.2007.10.004.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"476_CR15","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1586\/17512433.2014.884458","volume":"7","author":"MW Stewart","year":"2014","unstructured":"Stewart MW. Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF. Expert Rev Clin Pharmacol. 2014;7(2):167\u201380. https:\/\/doi.org\/10.1586\/17512433.2014.884458.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"476_CR16","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.preteyeres.2008.09.001","volume":"27","author":"SG Jarrett","year":"2008","unstructured":"Jarrett SG, Lin H, Godley BF, Boulton ME. Mitochondrial DNA damage and its potential role in retinal degeneration. Prog Retin Eye Res. 2008;27:596\u2013607.","journal-title":"Prog Retin Eye Res"},{"key":"476_CR17","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0014-4835(03)00023-X","volume":"76","author":"FQ Liang","year":"2003","unstructured":"Liang FQ, Godley BF. Oxidative stress-induced mitochondrial DNA damage in human retinal pigment epithelial cells: a possible mechanism for RPE aging and age-related macular degeneration. Exp Eye Res. 2003;76:397\u2013403.","journal-title":"Exp Eye Res"},{"key":"476_CR18","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.neurobiolaging.2005.05.012","volume":"27","author":"J Feher","year":"2006","unstructured":"Feher J, Kovacs I, Artico M, Cavallotti C, Papale A, Balacco GC. Mitochondrial alterations of retinal pigment epithelium in age-related macular degeneration. Neurobiol Aging. 2006;27:983\u201393.","journal-title":"Neurobiol Aging"},{"key":"476_CR19","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.mito.2006.12.002","volume":"7","author":"J Fukae","year":"2007","unstructured":"Fukae J, Mizuno Y, Hattori N. Mitochondrial dysfunction in Parkinson\u2019s disease. Mithochondrion. 2007;7:58\u201362.","journal-title":"Mithochondrion"},{"key":"476_CR20","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/ng.170","volume":"40","author":"LG Fritsche","year":"2008","unstructured":"Fritsche LG, Loenhardt T, Janssen A, Fisher SA, Rivera A, Keilhauer CN, Weber BH. Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA. Nat Genet. 2008;40:892\u20136.","journal-title":"Nat Genet"},{"issue":"12","key":"476_CR21","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1016\/j.ophtha.2015.08.015","volume":"122","author":"GS Yinq","year":"2015","unstructured":"Yinq GS, Maguire MG, et al. Association of baseline characteristics and early vision response with 2-year vision outcomes in the comparison of AMD treatments Trials (CATT). Ophthalmology. 2015;122(12):2523\u201331.","journal-title":"Ophthalmology"},{"key":"476_CR22","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1167\/iovs.04-1327","volume":"46","author":"MV Micali","year":"2005","unstructured":"Micali MV, Jazwinski SM. Nuclear gene expression changes due to michocondrial dysfunction in ARPE-19 cells: implications for age-related macular degeneration. Invest Ophthalmol Vis Sci. 2005;46:1765\u201373.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"476_CR23","doi-asserted-by":"crossref","unstructured":"Chomyn A. Platelet-mediated transformation of human mitochondrial DNA-less cells. In: Rubin B, Editor. Methods in Enzymology, vol. 264. Salt Lake City, UT: Academic Press, Inc.; 1996. p. 334\u2013339.","DOI":"10.1016\/S0076-6879(96)64031-2"},{"key":"476_CR24","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.1167\/iovs.08-2646","volume":"50","author":"N Udar","year":"2007","unstructured":"Udar N, Atilano SR, Memarzadeh M, Boyer D, Chwa M, et al. Mitochondrial DNA haplogroups and age-related macular degeneration. Invest Ophthalmol Vis Sci. 2007;50:2966\u201374.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"476_CR25","doi-asserted-by":"crossref","unstructured":"Atilano SR, Abedi S, Ianopol NV, Singh MK, Norman JL, Malik D, Falatoonzadeh P, Chwa M, Nesburn AB, Kuppermann BD, Kenney MC. Differential epigenetic status and responses to stressors between retinal cybrids cells with African versus European mitochondrial DNA: Insights into disease susceptibilities. Cells. 2022;26;11(17):2655.","DOI":"10.3390\/cells11172655"},{"key":"476_CR26","doi-asserted-by":"publisher","first-page":"e2951","DOI":"10.1038\/cddis.2017.348","volume":"8","author":"S Nashine","year":"2017","unstructured":"Nashine S, Cohen P, Chwa M, Lu S, Nesburn AB, Kuppermann BD, Kenney MC. Human G (HNG) portects age-related macular degenertaion (AMD) transmitochondrial ARPE-19 cybrids from mitochondrial and cellular damage.  Cell Death Disease. 2017; 20;8(7):e2951.","journal-title":"Cell Death Dis"},{"key":"476_CR27","doi-asserted-by":"crossref","unstructured":"Abedi S, Yung G, Atilano SR, Thaker K, Chang S, Chwa M, Udar N, Bota D, Kenney MC. Differential effects of cisplatin on cybrid cells with varying mitochondrial DNA haplogroups. PeerJ. 2020;1;8:e9908.","DOI":"10.7717\/peerj.9908"},{"key":"476_CR28","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1146\/annurev.bi.61.070192.005523","volume":"61","author":"DC Wallace","year":"1992","unstructured":"Wallace DC. Diseases of the mitochondrial DNA. Annu Rev Biochem. 1992;61:1175\u2013212.","journal-title":"Annu Rev Biochem"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-023-00476-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-023-00476-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-023-00476-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T04:03:25Z","timestamp":1690257805000},"score":1,"resource":{"primary":{"URL":"https:\/\/journalretinavitreous.biomedcentral.com\/articles\/10.1186\/s40942-023-00476-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,25]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["476"],"URL":"https:\/\/doi.org\/10.1186\/s40942-023-00476-7","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,25]]},"assertion":[{"value":"10 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Rodrigo Donato Costa: No competing interests Farid Jos\u00e9 Thomaz Neto: No competing interests M. Tarek Moustafa: No competing interests Shari R. Atilano: No competing interests Marilyn Chwa: No competing interests Javier C\u00e1ceres-del-Carpi: No competing interests Mohamed Hamid Mohamed: No competing interests M. Cristina Kenney: No competing interests Baruch D. Kuppermann: Clinical Research: Allegro Ophthalmics, Allergan, Genentech Inc, Ionis, IVERIC Bio, Novartis Pharmaceuticals, Regeneron Pharmaceuticals Inc, RegenXBio Consultant: Allegro Ophthalmics, Allergan, Aviceda Therapeutics, Clearside, EyeBio, Eyedaptic, Genentech Inc, Glaukos Corporation, InflammX Therapeutics, IVERIC Bio, jCyte, Novartis Pharmaceuticals, Regeneron Pharmaceuticals Inc, ReVana Therapeutics, Ripple Therapeutics, Theravance Biopharma Speaker Bureau: Allergan, Genentech.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}